MarketFriction

Strides Pharma Science Ltd

NSE STAR · BSE 532531 · Pharmaceuticals
₹1,084.80 -3.14%
NSE close2026-10-01
52 week range768.65 - 1,260.90
Market cap₹10,808 Cr.
P/E18.7
Microcap 250 Price band 20% Delivery 52.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales9991,0061,0441,0541,1671,1541,1901,1201,2211,1951,3231,265
Expenses8898768748669839439739029909591,0841,037
Operating Profit111129169188184210218218231236240228
OPM %11%13%16%18%16%18%18%19%19%20%18%18%
Other Income-12960-273,299254-12018104368
Interest797071737452504746434241
Depreciation604948474848494950515356
Profit before tax-15770233,36986114106122153245148200
Tax %-5%23%55%1%16%21%20%13%14%15%13%17%
Net Profit-14954103,350729086106132208129165
EPS in Rs-14.545.401.98364.697.819.548.9110.8013.8421.9313.7717.02
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,8612,7552,8452,1782,7523,3163,0703,6883,8904,5654,8595,004
Expenses2,4862,2282,4481,9822,3382,7793,2013,5443,3623,7633,9334,070
Operating Profit374527398197414537-131145528803925935
OPM %13%19%14%9%15%16%-4.3%3.9%14%18%19%19%
Other Income63291643303-43109-11292-1003,313124193
Interest16818319679156150177261280249179172
Depreciation131126154117174206233243214192202210
Profit before tax13750969030342289-653-268-653,675669746
Tax %31%12%1%-9%27%11%-27%-21%45%2%14%
Net Profit9544668433031258-474-212-943,598575634
EPS in Rs12.1544.7174.2536.274.0629.93-51.25-22.44-7.68389.7560.3466.56
Dividend Payout %41%10%3%8%345%8%0%-7%-33%1%8%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth5%8%10%8%
Compounded Profit Growth16%20%71%55%
Stock Price CAGR10%34%70%43%
Return on Equity22%31%57%20%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital608989909090909090929292
Reserves1,0852,5692,6592,3742,5592,4382,6872,2692,1222,0342,4603,015
Borrowings8923,5423,7002,5203,2212,2352,3483,0253,0302,5171,8801,758
Other Liabilities4381,2111,5981,6011,9371,3691,8441,5561,3521,1571,4981,941
Total Liabilities2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807
Fixed Assets7012,6792,9802,9773,6482,0992,2192,3472,3111,8651,8992,101
CWIP171815780620453413447291151162207447
Investments6301,3411,525588702549697540490303409291
Other Assets9722,5762,7622,4003,0053,0703,6053,7623,6423,4703,4143,967
Total Assets2,4757,4108,0466,5857,8076,1316,9696,9406,5945,7995,9296,807
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity837328818760205481-25844701684703
Cash from Investing Activity50-2,205-1,222570-1451,321-522-119302-150-90-173
Cash from Financing Activity-4212,944338-1,016194-1,709-16421-214-693-643-453
Net Cash Flow-288812-596-259110-184-5645133-142-4876
Free Cash Flow-157-293-386-212-25658188-326-43672505291
CFO/OP61%40%66%61%59%60%60%199%-30%128%77%84%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1191321321131651241221441291079697
Inventory Days135149209146294254329285257235236305
Days Payable153188221188299259323260220178190244
Cash Conversion Cycle1029212071160119128168165164141157
Working Capital Days-916-122-4-70-70-22-28-11-192438
ROCE %57%8%11%16%2%5%8%-5%-0%7%15%18%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters27.79%27.39%25.88%25.86%25.84%26.82%28.30%28.30%27.86%27.86%27.91%27.91%
FIIs17.25%19.45%24.57%26.71%30.08%28.48%28.32%28.02%28.51%29.52%28.68%28.40%
DIIs19.50%19.02%17.66%18.17%18.24%16.92%13.72%13.30%12.98%13.02%14.44%15.42%
Government0.40%0.39%0.39%0.39%0.01%0.01%0.01%0.01%0.01%0.01%0.01%0.01%
Public35.06%33.75%31.52%28.87%25.83%27.78%29.65%30.38%30.62%29.59%28.96%28.28%
No. of Shareholders1,01,63891,18284,69591,91796,0091,14,23695,12592,88991,20685,58986,61694,850

Fundamentals

Market Cap₹ 10,808 Cr.
Current Price₹ 1,173
Stock P/E18.7
Book Value₹ 337
ROCE18.3 %
ROE20.0 %
Dividend Yield0.43 %
Face Value₹ 10.0
Compounded Sales Growth (TTM)8%
Compounded Profit Growth (TTM)55%
Consolidated figures.
Valuation
Market capRs 9,998 Cr
Enterprise valueRs 11,543 Cr
P/E (TTM)16.30x
Price to book3.22x
Price to sales2.00x
EV / EBITDA10.23x
EV / EBIT12.57x
EV / sales2.31x
Price to cash flow14.23x
Earnings yield6.14%
Dividend yield0.46%
P/E, 3-year average8.63x
P/B, 3-year average2.26x
P/E, 5-year average8.63x
P/B, 5-year average1.59x
Profitability
Operating margin (excl. other income)19.04%
Operating margin (incl. other income)21.60%
EBITDA margin22.54%
Pre-tax margin14.91%
Net profit margin12.26%
Net margin, latest quarter12.40%
ROE19.66%
ROCE18.23%
ROA8.73%
ROE, 3-year average56.68%
ROCE, 3-year average36.35%
ROA, 3-year average22.96%
ROE, 5-year average28.65%
ROCE, 5-year average19.98%
ROA, 5-year average11.85%
ROIC (approx.)16.95%
Tax rate14.08%
Other income / net worth4.00%
Growth
Sales growth (latest year)6.43%
Profit growth (latest year)-84.52%
Sales CAGR, 3 years9.62%
Sales CAGR, 5 years7.94%
Profit CAGR, 5 years15.68%
Sales growth QoQ-4.39%
Profit growth QoQ23.61%
Sales growth YoY (latest quarter)13.01%
Profit growth YoY (latest quarter)57.52%
Per share
EPS (TTM)Rs 66.57
EPS (latest year)Rs 60.35
EPS (latest quarter)Rs 17.03
EPS, 3-year averageRs 147.52
EPS, 5-year averageRs 73.78
Book value per shareRs 337.18
Sales per shareRs 542.99
Cash flow per shareRs 76.23
Free cash flow per shareRs 31.57
Dividend per share (latest year)Rs 5.00
Dividend per share, 3-year averageRs 3.83
Dividend per share, 5-year averageRs 3.25
Dividends
Dividend payout8.28%
Dividend payout, 3-year average4.66%
Dividend payout, 5-year average4.66%
Efficiency
Asset turnover0.71x
Fixed asset turnover2.31x
Inventory turnover1.48x
Inventory days247 days
Debtor days97 days
Debtors turnover3.77x
Creditor days244 days
Cash conversion cycle157 days
Working capital days38 days
Leverage
Total debtRs 1,758 Cr
Cash and bankRs 213 Cr
Net debtRs 1,545 Cr
Debt to equity0.57x
Net debt / EBITDA1.37x
Interest coverage5.35x
Current ratio (filing 2026-03-31)1.25x
Quick ratio (filing 2026-03-31)0.68x
Trade payables (filing 2026-03-31)Rs 1,310 Cr
Owners' fund to total sources45.66%
Debt to assets25.83%
Cash flow
Cash from Operating Activity (latest year)Rs 703 Cr
Cash from Investing Activity (latest year)Rs -173 Cr
Cash from Financing Activity (latest year)Rs -453 Cr
Net Cash Flow (latest year)Rs 76 Cr
Free cash flow (latest year)Rs 291 Cr
FCFE (approx.: FCF + change in debt)Rs 169 Cr
Cash from ops / profit, 5 years0.55x
Sales to cash flow6.92x
Statement figures
Net sales (TTM)Rs 5,004 Cr
Net sales (latest year)Rs 4,859 Cr
Sales (latest quarter)Rs 1,265 Cr
Operating profit excl. other income (latest year)Rs 925 Cr
Operating profit (latest quarter)Rs 228 Cr
Other income (TTM)Rs 193 Cr
EBITDA (TTM)Rs 1,128 Cr
PBDT (TTM)Rs 956 Cr
Profit before tax (TTM)Rs 746 Cr
Tax (latest year)Rs 94 Cr
Net profit (TTM)Rs 613 Cr
Net profit (latest year)Rs 556 Cr
Net profit (latest quarter)Rs 157 Cr
Depreciation (TTM)Rs 210 Cr
Depreciation (latest quarter)Rs 56 Cr
Interest (TTM)Rs 172 Cr
Cost of goods sold (latest year)Rs 2,417 Cr
Total expenditure (latest year)Rs 3,933 Cr
Total income (latest year)Rs 4,983 Cr
Share capitalRs 92 Cr
ReservesRs 3,015 Cr
Shareholders' fundsRs 3,108 Cr
Total assetsRs 6,807 Cr
Net blockRs 2,101 Cr
Capital work in progressRs 447 Cr
InvestmentsRs 291 Cr
ReceivablesRs 1,289 Cr
InventoryRs 1,635 Cr
Other liabilitiesRs 1,941 Cr
Shares outstanding (crore)9.22
Ownership
Promoter holding27.91% (-0.39 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 16.3 is at the 51th percentile of its own 6.8-year range (median 15.4, low 1.6, high 222.4).
P/B 3.22 is at the 81th percentile (median 2.20).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodSTARNifty 50Difference
1 week-9.8%-2.8% -7.0 pts
1 month+5.9%-6.8% +12.7 pts
3 months-3.7%-7.6% +3.9 pts
6 months+15.7%+0.4% +15.3 pts
1 year+29.2%-9.9% +39.2 pts
2 years-20.2%-13.6% -6.6 pts
3 years+113.5%+14.2% +99.3 pts
5 years+86.1%+27.9% +58.2 pts
16 mutual fund schemes hold about ₹926 Cr. Over three months 1 bought more and 14 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Quant Small Cap Fund1.06%376 -9%
Bandhan Small Cap Fund0.77%262 +38%
Quant Multi Cap Fund1.89%146 -2%
Axis Small Cap Fund0.24%75 -9%
Aditya Birla SL Value Fund0.54%38 -7%
Motilal Oswal Nifty Microcap 250 Index Fund0.71%18 -9%
Quant Healthcare Fund2.45%10 -11%
Groww Nifty Total Market Index Fund0.03%0 -5%
Bandhan BSE Healthcare Index Fund0.42%0 -7%
Angel One Nifty Total Market Index Fund0.03%0 -5%
Mirae Asset Nifty Total Market Index Fund0.03%0 -5%
Motilal Oswal BSE 1000 Index Fund0.03%0 -5%
Bandhan Nifty Total Market Index Fund0.03%0 -5%
Samco Multi Cap Fund0.00%0 -100%
JioBlackRock Flexi Cap Fund0.00%0 -100%
WOC Pharma and Healthcare Fund0.00%0 -100%

Red flags

F-score 6 of 8
lookAuditor change Auditor change 2026-05-18: Strides Pharma Science Limited has informed the Exchange regarding Change in Auditors of the company.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Latest quarter

Jun 2026
Sales ₹1,265 Cr +12.9% vs Jun 2025. Net profit ₹165 Cr +55.7%.
Against our estimate for Jun 2026: sales +5.2%, profit +33.5% in line. Our estimate for Sep 2026: sales Rs 1,368 Cr, profit Rs 163 Cr (how).

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-31Dividend - Rs 5 Per Share
2025-07-22Dividend - Rs 4 Per Share
2024-12-06Demerger
2024-09-09Dividend - Rs 2.50 Per Share
2023-08-04Dividend - Rs 1.50 Per Share
2021-08-05 Dividend - Rs 2.50 Per Share
2020-07-24 Annual General Meeting/Dividend - Rs 2 Per Share
2019-08-22 Interim Dividend - Rs 12 Per Share
2019-07-19 Annual General Meeting/Dividend - Rs 3 Per Share
2018-09-12 Annual General Meeting/Dividend Rs 2 Per Share
2018-04-06 Scheme Of Arrangement
2017-09-07 Annual General Meeting/Dividend - Rs 4.50 Per Share
2016-07-21 Annual General Meeting/ Dividend - Rs 4/- Per Share
2015-07-22Annual General Meeting/ Dividend - Rs 3/- Per Share
2014-10-16Special Dividend Rs.105/- Per Share
2014-09-01Annual General Meeting / Dividend - Rs 5/- Per Share
2013-12-19Special Dividend - Rs 500/- Per Share
2013-05-30Annual General Meeting And Dividend Rs.2/- Per Share
2012-05-14Annual General Meeting And Dividend Rs.2/- Per Share
2011-05-18Annual General Meeting And Dividend Rs.1.50 Per Share
2010-05-21Annual General Meeting And Dividend Rs.1.50 Per Share
2009-04-16Annual General Meeting
2008-06-19Agm
2007-06-12Agm/Dividend-20%
2006-06-06Agm/Final Dividend-20%
DateTypeWhat it says
2026-09-23General UpdatesSustainability Report for FY26.
2026-09-11General UpdatesCompletion of USFDA Inspection at the Company s Formulations Facility at Alathur
2026-08-19Press ReleaseA press release dated August 19, 2026, titled "Strides receives USFDA Establishment Inspection Report (EIR) for flagship facility in Bengaluru".
2026-08-18Shareholder meetingVoting results.
2026-08-14Shareholder meetingProceedings of Annual General Meeting held on August 14, 2026
2026-08-03Concall / analyst meetTranscript of Earnings Call pertaining to Unaudited Financial Results of the Company for the quarter ended June 30, 2026.
2026-07-31Concall / analyst meetThe link for Earnings Call pertaining to unaudited financial results for Q1 FY27
2026-07-31General UpdatesInvestor Presentation for Earnings call on Q1 FY 2027
2026-07-31Press ReleaseA press release dated July 31, 2026, titled "Strides Delivers Steady Performance with Q1FY27; Revenue at ₹12,654m, Grew 13% YoY; Ex-US Markets G...
2026-07-31Board meeting outcomeStrides Pharma Science Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-24Concall / analyst meetEarnings Call to discuss the Unaudited Financial Results of the Company for the quarter ended June 30, 2026
2026-07-21General UpdatesBusiness Responsibility and Sustainability Report for FY 2026
2026-07-21Shareholder meetingNotice of Annual General Meeting to be held on August 14, 2026
2026-07-20Record DateRecord date for the purpose of Dividend is 31-Jul-2026.
2026-07-03Sale or disposalUpdate on completion of transaction relating to Pivot Path.
2026-06-27Sale or disposalStrides Partners with Ascent Capital to Unlock Value in Pivot Path
2026-06-27Press ReleaseA press release dated Jun 27, 2026, titled "Strides Partners with Ascent Capital to Unlock Value in Pivot Path".
2026-06-08Concall / analyst meetSchedule of meet
2026-06-01General UpdatesIntimation under Regulation 30 of SEBI (LODR) Regulations, 2015 pertaining to reminder to Shareholders regarding Unclaimed Dividends and Transfer to I...
2026-06-01General UpdatesSTAR: Strides Pharma Science Limited has informed Effective Date for the Scheme of Demerger involving Arco Lab Private Limited ( Arco Lab ) and Pivot ...
2026-05-28Concall / analyst meetSchedule of meet
2026-05-28Concall / analyst meetSchedule of meet
2026-05-28Concall / analyst meetSchedule of meet
2026-05-28Concall / analyst meetSchedule of meet
2026-05-28Concall / analyst meetSchedule of meet
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Strides Pharma Science Ltd?

Strides Pharma Science Ltd (STAR) has a market capitalisation of Rs 10,808 Cr. at the 2026-10-01 close.

What is the P/E ratio of Strides Pharma Science Ltd?

Strides Pharma Science Ltd trades at a P/E of 18.7 on trailing twelve-month profit, at the 2026-10-01 close.

What were Strides Pharma Science Ltd's latest quarterly results?

In the Jun 2026 quarter, Strides Pharma Science Ltd sales was Rs 1,265 Cr (+12.9% vs Jun 2025) and net profit was Rs 165 Cr.

What is the 52-week high and low of Strides Pharma Science Ltd?

The 52-week high is Rs 1,260.90 and the 52-week low is Rs 768.65.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03